CMGANTi008-A

iPSC_MFS_FBN1_Fi930129_C8

General

Cell Line

hPSCreg name CMGANTi008-A
Cite as:
CMGANTi008-A (RRID:CVCL_D0D7)
Alternative name(s)
iPSC_MFS_FBN1_Fi930129_C8
Cell line type Human induced pluripotent stem cell (hiPSC)
Similar lines
UGENTi001-A-1
(UGENT-MFS003-CRISPR)
Donor diseases:
Marfan Syndrome
ZJUi009-A
(ZJULLi001-A)
Donor diseases:
Marfan Syndrome
UGENTi001-A
(UGENT-MFS003)
Donor diseases:
Marfan Syndrome
INSRMe013-A
(STR-I-301-MFS)
Donor diseases:
Marfan syndrome
ISMMSi001-A
(SAMEA104275576, MFS44-E)
Donor's gene variants:
FBN1, FBN1
Donor diseases:
Marfan syndrome
CMGANTi005-A
(iPSC_MFS_FBN1_MCE-KB_C8)
Donor diseases:
Marfan Syndrome
ISMMSi001-B
(SAMEA104275577, MFS44-16)
Donor's gene variants:
FBN1, FBN1
Donor diseases:
Marfan syndrome
RGIe062-A
(SI-154)
Donor diseases:
Marfan syndrome
ISMMSi002-A
(SAMEA104275578, MFS60-12)
Donor's gene variants:
FBN1, FBN1
Donor diseases:
Marfan syndrome
ISMMSi002-B
(MFS60-3-1, SAMEA104276575)
Donor's gene variants:
FBN1, FBN1
Donor diseases:
Marfan syndrome
VUBe008-A
(VUB08_MFS)
Donor diseases:
Marfan syndrome
LUMCi056-A
(CRB1 patient 128 compound heterozygous c.2843G>A p.(Cys948Tyr) and c.3122T>C p.(Met1041Thr), LUMC0128iCRB01)
Donor's gene variants:
CRB1, CRB1
Donor diseases:
Retinitis Pigmentosa
LUMCi030-B
(LUMC0110iALK10)
Donor diseases:
Hereditary Hemorrhagic Telangiectasia
LUMCi030-A
(LUMC0110iALK04)
Donor diseases:
Hereditary Hemorrhagic Telangiectasia
Last update 20th February 2023
User feedback
No feedback available yet.

Login to share your feedback, experiences or results with the research community.

Provider

Generator Center of Medical Genetics Antwerp (CMGANT)
Owner Center of Medical Genetics Antwerp (CMGANT)
Distributors
Derivation country Belgium

External Databases

BioSamples SAMEA112366464
Cellosaurus CVCL_D0D7
Wikidata Q123030953

General Information

Publications
* Is the cell line readily obtainable for third parties?
Yes
Research use: allowed
Clinical use: not allowed
Commercial use: not allowed

Donor Information

General Donor Information

Sex male
Ethnicity white Belgian

Phenotype and Disease related information (Donor)

Diseases A disease was diagnosed.
The donor is a carrier of a disease-associated mutation and affected.
Synonyms
  • Marfan Syndrome
  • Marfan's Syndrome
  • Marfan syndrome
Is the medical history available upon request? Yes
Is clinical information available? Yes

Karyotyping (Donor)

Has the donor karyotype been analysed?
Yes
46, XY. No clinically significant abnormalities observed.
Karyotyping method: Molecular karyotyping by SNP array
http://

Other Genotyping (Donor)

Is there genome-wide genotyping or functional data available?
No

External Databases (Donor)

BioSamples SAMEA112366766

Ethics

Has informed consent been obtained from the donor of the embryo/tissue from which the pluripotent stem cells have been derived? Yes
Was the consent voluntarily given? Yes
Has the donor been informed that participation will not directly influence their personal treatment? Yes
Can you provide us with a copy of the Donor Information Sheet provided to the donor? Yes
Do you (Depositor/Provider) hold the original Donor Consent Form? Yes
Alternatives to consent are available? No
Is there other documentation provided to the donor for consenting purposes? No
Confirm that consent was obtained by a qualified professional Yes
Has the donor agreed to be re-contacted? Unknown
Has the donor been informed about how her/his data will be protected? Yes
Please indicate whether the data associated with the donated material has been pseudonymised or anonymised. pseudonymised
Does consent explicitly allow the derivation of pluripotent stem cells? Yes
Does consent expressly prevent the derivation of pluripotent stem cells? No
Does consent pertain to a specific research project? Yes
Details on restriction to research project Study of inherited cardiovascular diseases
Does consent permit unforeseen future research, without further consent? No
Does the consent permit uses of donated embryo/tissue or derived cell line intended for clinical treatment or human applications? No
Does consent expressly prevent development of commercial products? No
Does consent expressly prevent financial gain from any use of the donated embryo/tissue, including any product made from it? No
Does consent expressly permit storage of donated embryo/tissue for an unlimited time? No
Does consent expressly permit storage of cells derived from the donated embryo/tissue for an unlimited time? No
Does consent prevent the DONATED BIOSAMPLE from being made available to researchers anywhere in the world? No
Does consent prevent CELLS DERIVED FROM THE DONATED BIOSAMPLE from being made available to researchers anywhere in the world? No

Does consent permit research by

an academic institution? Yes
a public organisation? Yes
a non-profit company? Yes
a for-profit corporation? No
Does consent expressly permit collection of genetic information? Yes
Does consent expressly permit storage of genetic information? Yes
Does consent prevent dissemination of genetic information? No
Has the donor been informed that their donated biosample or derived cells may be tested for the presence of microbiological agents / pathogens? No
Has the donor consented to receive information discovered during use of donated embryo/tissue that has significant health implications for the donor? Yes
How may genetic information associated with the cell line be accessed? Controlled Access
Will the donor expect to receive financial benefit, beyond reasonable expenses, in return for donating the biosample? No
Does the consent anticipate that the donor will be notified of results or outcomes of any research involving the donated samples or derived cells? No
Does the consent permit the donor, upon withdrawal of consent, to stop the use of the derived cell line(s) that have already been created from donated samples? Yes
Does the consent permit the donor, upon withdrawal of consent, to stop delivery or use of information and data about the donor? Yes
Does consent permit access to medical records of the donor? Yes
Please describe how access is provided: Through the treating physician
Does consent permit access to any other source of information about the clinical treatment or health of the donor? Yes
Contact data, institution, or website:
Has a favourable opinion been obtained from a research ethics committee, or other ethics review panel, in relation to the Research Protocol including the consent provisions? Yes
Name of accrediting authority involved? UZA ethics committee
Approval number 20/08/087
Has a favourable opinion been obtained from a research ethics committee, or other ethics review panel, in relation to the PROPOSED PROJECT, involving use of donated embryo/tissue or derived cells? Yes
Name of accrediting authority involved? UZA ethics committee
Approval number 20/08/087
Do you have obligations to third parties in regard to the use of the cell line? No
Are you aware of any further constraints on the use of the donated embryo/tissue or derived cells? No
Is there an MTA available for the cell line? No
For generation of the cell line, who was the supplier of any recombined DNA vectors or commercial kits used? CytoTune™-iPS 2.0 Sendai Reprogramming Kit from Invitrogen / ThermoFisher Scientific
Are you aware of any constraints on the use or distribution of the cell line from the owner or any parties identified in the query above? No

hIPSC Derivation

General

Source cell type
Source cell origin
Passage number reprogrammed 6

Reprogramming method

Vector type Non-integrating
Vector Sendai virus
Is reprogramming vector detectable?
No
Methods used
RT-PCR
Notes on reprogramming vector detection SeV not detected on passage 10

Vector free reprogramming

Type of used vector free reprogramming factor(s)
None

Other

Selection criteria for clones Clones were picked based on morphology (round, flat colonies with smooth edges and tightly packed cells) for 5 rounds and subsequently passaged using EDTA for 5 more rounds. Only clones with nice morphology and no differentiation after these 10 passaging rounds were selected.
Derived under xeno-free conditions
No
Derived under GMP?
Yes
Available as clinical grade?
No

Culture Conditions

Surface coating Matrigel/Geltrex
Feeder cells
No
Passage method Enzyme-free cell dissociation
EDTA
O2 Concentration 21 %
CO2 Concentration 5 %
Medium Essential 8™ Flex
Has Rock inhibitor (Y27632) been used at passage previously with this cell line?
Yes
Has Rock inhibitor (Y27632) been used at cryo previously with this cell line?
No
Has Rock inhibitor (Y27632) been used at thaw previously with this cell line?
Yes

Characterisation

Analysis of Undifferentiated Cells
Marker Expressed Immunostaining RT-PCR Flow Cytometry Enzymatic Assay Expression Profiles
SOX2
Yes
POU5F1 (OCT-4)
Yes
DNMT3B
Yes
Marker Present Absent
mCpG
OCT4 X
Differentiation Potency
Endoderm
Ont Id: UBERON_0000925
Marker Expressed
CXCR4
Yes
SOX17
Yes
FOXA2
Yes
Mesoderm
Ont Id: UBERON_0000926
Marker Expressed
NKX2.5
Yes
ASMA
Yes
DCN
Yes
Ectoderm
Ont Id: UBERON_0000924
Marker Expressed
PAX6
Yes
MAP2
Yes
HES5
Yes

Microbiology / Virus Screening

Mycoplasma Negative

Genotyping

Karyotyping (Cell Line)

Has the cell line karyotype been analysed?
Yes
46, XY. No clinically significant abnormalities observed.
Passage number: 11
Karyotyping method: Molecular karyotyping by SNP array
http://

Other Genotyping (Cell Line)

Is there genome-wide genotyping or functional data available?
Yes
SNP typing array